PubRank

Susan S Smyth

Author PubWeight™ 72.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest 2005 2.46
2 Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood 2011 2.27
3 Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol 2011 1.81
4 Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A 2010 1.80
5 Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem 2009 1.78
6 Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2006 1.52
7 Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway. Atherosclerosis 2009 1.33
8 Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets 2008 1.27
9 Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol 2009 1.23
10 Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol 2012 1.21
11 Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res 2008 1.20
12 Characterization of a model to independently study regression of ventricular hypertrophy. J Surg Res 2007 1.19
13 Src family kinases mediate neutrophil adhesion to adherent platelets. Blood 2006 1.16
14 Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am J Respir Crit Care Med 2013 1.15
15 Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J Biol Chem 2011 1.11
16 Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res 2013 1.11
17 Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions. Clin Sci (Lond) 2011 1.10
18 Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice. J Lipid Res 2013 1.09
19 Mice with targeted inactivation of ppap2b in endothelial and hematopoietic cells display enhanced vascular inflammation and permeability. Arterioscler Thromb Vasc Biol 2014 1.08
20 A phosphatidic acid binding/nuclear localization motif determines lipin1 function in lipid metabolism and adipogenesis. Mol Biol Cell 2010 1.07
21 Src-family kinases mediate an outside-in signal necessary for beta2 integrins to achieve full activation and sustain firm adhesion of polymorphonuclear leucocytes tethered on E-selectin. Biochem J 2006 1.05
22 Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun 2013 1.05
23 Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia. Arterioscler Thromb Vasc Biol 2012 1.04
24 CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 2006 1.04
25 Platelets as immune mediators: their role in host defense responses and sepsis. Thromb Res 2010 1.04
26 Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res 2013 1.03
27 Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol 2009 1.03
28 Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler Thromb Vasc Biol 2008 1.02
29 Distinct roles for Rap1b protein in platelet secretion and integrin αIIbβ3 outside-in signaling. J Biol Chem 2011 1.01
30 Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Heart Circ Physiol 2009 0.99
31 Evidence of mobilization of pluripotent stem cells into peripheral blood of patients with myocardial ischemia. Exp Hematol 2010 0.92
32 Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Biochem J 2011 0.91
33 Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. Int J Biochem Cell Biol 2010 0.91
34 Functional characterization of the atypical integral membrane lipid phosphatase PDP1/PPAPDC2 identifies a pathway for interconversion of isoprenols and isoprenoid phosphates in mammalian cells. J Biol Chem 2010 0.90
35 Measurement of autotaxin/lysophospholipase D activity. Methods Enzymol 2007 0.90
36 Platelet secretion and hemostasis require syntaxin-binding protein STXBP5. J Clin Invest 2014 0.89
37 Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling. Arterioscler Thromb Vasc Biol 2011 0.87
38 Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction. Stem Cells Dev 2013 0.87
39 Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis 2009 0.86
40 CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury. PLoS One 2011 0.85
41 Parent-of-origin effects on cardiac response to pressure overload in mice. Am J Physiol Heart Circ Physiol 2009 0.84
42 Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol 2007 0.84
43 Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis 2013 0.84
44 Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation. Trends Cardiovasc Med 2009 0.84
45 Synergistic effect of anemia and red blood cells transfusion on inflammation and lung injury. Adv Hematol 2012 0.83
46 Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration. FASEB J 2013 0.83
47 Coronary artery remodeling in a model of left ventricular pressure overload is influenced by platelets and inflammatory cells. PLoS One 2012 0.83
48 Lysophosphatidic acid and cardiovascular disease: seeing is believing. J Lipid Res 2013 0.82
49 Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol 2012 0.81
50 Lysophospholipids in coronary artery and chronic ischemic heart disease. Curr Opin Lipidol 2015 0.81
51 Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost 2014 0.80
52 Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study. J Thromb Thrombolysis 2012 0.79
53 Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. J Thromb Thrombolysis 2011 0.79
54 Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B. Cardiol Rev 2015 0.79
55 Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol 2013 0.79
56 Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. Circ Cardiovasc Interv 2012 0.78
57 Enhanced platelet reactivity and thrombosis in Apoe-/- mice exposed to cigarette smoke is attenuated by P2Y12 antagonism. Thromb Res 2010 0.78
58 Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscler Thromb Vasc Biol 2010 0.78
59 The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism. PLoS One 2012 0.78
60 Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. J Thromb Thrombolysis 2014 0.78
61 The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome. J Am Coll Cardiol 2015 0.77
62 Pathophysiology and pharmacologic treatment of venous thromboembolism. Curr Drug Targets 2014 0.77
63 Preventing platelet thrombosis with a PAR1 pepducin. Circulation 2012 0.77
64 Novel mediators and biomarkers of thrombosis. J Thromb Thrombolysis 2014 0.77
65 The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis 2015 0.77
66 Tissue necrosis factor α and targeting its receptor in ischaemic heart disease. Heart 2013 0.76
67 In-stent restenosis: more fuel for the fire. Am Heart J 2002 0.76
68 Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J 2010 0.75
69 Platelet function analysis: at the edge of meaning. Thromb Haemost 2009 0.75
70 Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions. Curr Cardiol Rev 2016 0.75
71 Targeting platelet thrombin receptor signaling to prevent thrombosis. Pharmaceuticals (Basel) 2013 0.75
72 Connexin 37 counteracts clotting. Circulation 2011 0.75
73 Invasive coronary vasoreactivity testing to diagnose microvascular dysfunction in women. JACC Cardiovasc Interv 2012 0.75
74 Fibrinolytic therapy versus primary percutaneous coronary interventions for ST-segment elevation myocardial infarction in Kentucky: time to establish systems of care? South Med J 2013 0.75
75 A case report of simultaneous thrombosis of two coronary artery stents in association with clopidogrel resistance. Clin Cardiol 2007 0.75
76 Anti-platelet therapy. Curr Drug Targets 2011 0.75
77 Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother 2007 0.75
78 The case against routine aspirin use for primary prevention in low-risk adults. Am Fam Physician 2011 0.75
79 Platelet-mediated thrombosis and drug-eluting stents. Circ Cardiovasc Interv 2011 0.75